{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreienkopsz43scfq2v3hmauxiagoecynhdukqc3i5wmy7zyy6lvbry4",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mjnfquy7e5s2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreifyr7ldu4h4yif24e5zgojtmu5rvekqo7fhigu7g2cgccngzmpize"
    },
    "mimeType": "image/jpeg",
    "size": 415057
  },
  "path": "/news/2026-04-global-trial-treatment-triple-negative.html",
  "publishedAt": "2026-04-16T16:20:05.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "A global, multicenter phase III trial, TROPION-Breast02, led by a senior medical oncologist and researcher from the National Cancer Centre Singapore, has demonstrated a significant breakthrough in improving the survival of patients with untreated, advanced triple negative breast cancer (TNBC) using the novel antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd). Published in the Annals of Oncology, the findings demonstrate the potential of Dato-DXd as an effective new treatment option for this aggressive disease.",
  "title": "Global trial shows novel treatment for triple-negative breast cancer nearly doubles survival"
}